Vistin Pharma is strongly committed to maintaining an open dialogue with our shareholders, potential investors, analysts, investment banks and the financial markets.

Our goal is for the share price to reflect the underlying value of the company by providing all price-relevant information to the market.
Last updated 29.03 2022 11:00
Nok 16,80
Since open-0,30 (-1.70%)
Since previous close +0,44 (+2.60%)

8 reasons for investing in Vistin Pharma ASA.

Leading Producer
Amongst Top 5 producers of metformin HCl globally
High Quality Reputation
Leading reputation as producer of high quality APIs with strong track record of customer delivery
Attractive Market Dynamics
Established position in growing metformin market
Diverse Client Portfolio
Established client base comprising mix of Big Pharma and leading generics players
Sustained Revenue Growth
Strong growth profile with double digit revenue growth in the last 5 years
Advanced Manufacturing Facilities
State of the art and dedicated manufacturing facility with potential for further expansion
Strong Leadership
Experienced management team with a strong track record
A Front-runner
Leading the ESG culture in the industry

Annual General Meeting 2024

Download resources

Quarterly Results

Annual Reports

Other downloads

Investor calendar

16.2.24
Q4 2023 Quarterly report
24.4.24
2023 Annual Report
24.4.24
Q1 Quarterly report
23.5.24
Annual General Meeting
23.8.24
Q2 and Half-Yearly report
31.10.24
Q3 Quarterly Report

Main shareholders

Per November 5th 2024

NAME

SHAREHOLDING

% SHARE

Imported item 22
Imported item 24
Imported item 23
1
INTERTRADE SHIPPING AS*
12 575 000
28,40 %
2
HOLMEN SPESIALFOND
4 200 379
8,66 %
3
PACTUM VEKST AS*
2 991 773
6,75 %
4
MP PENSJON PK
1 719 848
3,90 %
5
FERNCLIFF LISTED DAI AS*
1 234 280
2,80 %
6
STORKLEIVEN AS
751 000
1,70 %
7
AUGUST RINGVOLD AGENTUR AS
750 315
1,70 %
8
LUCELLUM AS
720 000
1,62 %
9
SAGA PURE ASA
700 000
1,45 %
10
HENRIK MIDTTUN HAAVIE
693 617
1,24 %
11
IVAR LØGES STIFTELSE
540 000
1,19 %
12
TIGERSTADEN AS
534 097
1,19 %
13
SURFSIDE HOLDING AS
527 960
1,15 %
14
TOM RAGNAR PRESTEGÅRD STAAVI
526 324
1,13 %
15
CORTEX AS
508 989
1,13 %
16
SANDEN EQUITY AS
500 000
1,11 %
17
DNB BANK ASA
500 000
0,92 %
18
WEM INVEST AS
415 000
0,90 %
19
DELTA AS
410 000
0,73 %
20
GINKO AS
400 000
0,68 %
Total 20 largest shareholders
30 446 255
68,35 %
Other shareholders
13 898 337
31,65 %
Total number of shares
44 344 592
100%
* Board members of Vistin Pharma, or companies controlled by Board members
Vistin Pharma - Oslo Stock Exchange

Contact

Alexander Karlsen
CFO
Vistin Pharma ASA
+47 970 53 621alexander.karlsen@vistin.com
Alexander Karlsen